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Abstract
Background: Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor intimately associated with Epstein-Barr
virus (EBV). NPC is a characteristic tumor displaying epidemiological, genetic and regional distribution properties that
makes it unique by its natural behavior.
Objectives: To assess the expression pattern of  LMP1 and p53 proteins in the different histological types of  NPC in a
sample of the Moroccan population and to define any association between the expression of those proteins with the sex,
the age and the histological types of NPC.
Methods: Archival formalin-fixed, paraffin-embedded NPC biopsies were evaluated in 23 Moroccan patients for the
presence of LMP1 and p53 using immunohistochemistry (IHC).
Results: No LMP1 expression was observed whereas 8 of  23 cases (34. 7%) had detectable p53 protein in the nuclei of
tumor cells. After statistical analysis according to the Fisher’s exact probability test, no significant association between p53
expression and histological type, age and sex distributions was demonstrated (p>0.05).
Conclusion: This study confirms that p53 overexpression is present in a subset of Moroccan NPC patients. Our results are
consistent with those reported by other studies concerning the same NPC endemic risk area and provide original data
concerning Morocco.
Keywords: Epidemiology, Epstein-Barr virus, Immunohistochemistry, LMP1, Moroccan, Nasopharyngeal carcinoma, p53,
Risk factors.
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Introduction
Nasopharyngeal carcinoma (NPC) is a malignant
epithelial neoplasm with a remarkable geographic
and racial distribution worldwide. Indeed, globally,
there are three distinct endemic areas: an area with
very high frequency in southern China (Canton),
where the incidence is 30 to 80/100 000/year1,2. An
area of  intermediate frequency (8 to 12/100 000/
year) in Taiwan, Vietnam, Thailand, Malaysia, the
Philippines, the Caribbean, the Mediterranean
(Maghreb and Middle East), Alaska and Greenland3.
And finally an area of   low frequency in North
China, Europe and the United States (0.5 to 2/100
000/year)4,5. In Morocco, the NPC incidence,
estimated to be about 4.6/100 000/year and
representing 5.3% of all cancers as reported by the
Cancer Registry of the Casablanca Region (RCRC)
published in 2007, is higher compared to Europe
and USA6,7. In addition, the Moroccans in France
are much more likely than French to be affected by
the NPC and for the French who lived in North
Africa, the incidence of NPC is 5.7 times greater
than those lived in France8.
A male preponderance of nasopharyngeal
carcinoma exists with a male-to-female ratio of
approximately 2-3:19. While in South China, most
NPC patients are between 40 and 60 years old, in
North Africa, the distribution of NPC according to
age is bi-modal. Beside the main peak of incidence
around 50 years old (80% cases), there is a secondary
peak between the age of 10 and 25 years old (juvenile
form) (20% cases)10.
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The etiology of  NPC is multifactorial and
currently available data suggest a complex interplay
of  genetic, viral, environmental and dietary factors.
Indeed, various human leukocyte antigens (HLA),
such as HLA-A2, HLA-B17 and HLA-Bw46, are
important etiologic or prognostic indicators in
NPC11. As well, Epstein-Barr virus (EBV) is
consistently detected in patients with nasopharyngeal
carcinoma12,13, suggesting a role in the NPC
pathogenesis. In intermediate to high risk Chinese
populations, consumption of salted fish, especially
during weaning in childhood, is associated with
elevated risk of NPC 14. The carcinogenic potential
of  salt-preserved food can be explained by the
accumulation of significant levels of nitrosamines,
which are known for their carcinogenic properties15.
Salt-preserved fish also contain bacterial mutagens,
direct genotoxins, and EBV-reacting substances, any
or all of which could also contribute to the NPC
risk15.
In Maghrebian countries, associated foods
include quaddid (dried mutton stored in oil), harissa
(very spicy condiment prepared with red pepper,
olive oil, garlic, caraway) and toklia (basic stewing
preparation, contain red pepper, black pepper, garlic,
salt, oil, caraway and coriander) in Tunisia, pickled
fruit and vegetables, dried and salted fat, and rancid
butter in Setif, Algeria, and rancid butter and khelii
(dried meat, salty, spicy, cooked and preserved in a
mixture of oil and melted bovine greases) in
Morocco, have been suggested to be associated with
increased NPC risk16.
Other environmental factors such as
tobacco, cannabis and domestic cooking fumes intake
(cooking in the main living room) during childhood,
have recently been described as a risk factors for
NPC in North African countries 17. Furthermore, a
study subdividing Morocco into three zones of
variable incidence of NPC (North-Rif-Oriental,
Center-Middle Atlas, Haouz-South) revealed the
existence of a south-north gradient of exposure to
presumed risk factors, essentially bad living
conditions, food preservation agents and poor
hygiene 18. Lower socio-economic level has also been
reported as an important confounding factor for
NPC in China, Greenland and Tunisia19.
Epstein-Barr virus is a lymphotropic human
gamma herpesvirus which infects more than 90%
individuals in the human population20. EBV has been
classified as a type I carcinogen by the World Health
Organization (WHO) due to its etiological
implication  in the pathogenesis of several human
malignancies including Burkitt’s and Hodgkin’s
lymphomas, gastric carcinoma and NPC 21. EBV
infection in NPC is classified as type II latent infection
in which only EBV nuclear antigen-1(EBNA-1),
latent membrane protein- 1(LMP1), LMP2, and EBV
early RNA (EBER) expressions can be detected 22.
Studies of  normal nasopharyngeal tissue and pre-
malignant biopsies indicate that genetic events, loss
of  heterozygosity at chromosomes 3p and 9p, occur
early in the pathogenesis of NPC, possibly as a result
of exposure to environmental cofactors such as
dietary components (salted fish), and that this might
predispose to subsequent EBV infection 23. Once
cells have become infected, EBV latent genes provide
growth and survival benefits, resulting in the
development of NPC 23. Among the molecules of
EBV latency, LMP1 (Latent membrane protein 1) is
the main oncogene of EBV because of its ability to
recruit an array of cellular genes and to inhibit
apoptosis by elevating Bcl-2 levels21, 22, 24
The p53 gene (TP53) is a tumor suppressor
gene frequently mutated in diverse malignant tumors.
It is codes for a 53-kDa cellular protein that leads to
the cell cycle arrest in G1 phase, after DNA damage,
in order to repair DNA or mediate cell apoptosis25.
Several studies have reported that, in NPC cases, a
high percentage of p53 protein expression were
detected by immunohistochemistry (IHC)26.
Overexpression of p53 is usually due to mutant p53,
which has a longer half-life as a result of decreased
degradation of  the protein27. Interestingly, for NPC,
other factors such as EBV may contribute to p53
protein overexpression.
In North Africa, contrasted frequencies of p53
accumulation in NPC were observed with regard
to the age distribution: there was significantly much
less p53-positive tumors in the group of young
patients (juvenile forms) than in the main age group
(above 30 years of age)28.
The aim of this study was to investigate the
expression of LMP1 and p53 proteins in the different
histological types of NPC in a sample of the
Moroccan population. We also attempted to define
any association between the expression of those
proteins with the sex, the age and the histological
types of  NPC. To this end we used
immunohistochemical technique on formalin fixed,
paraffin wax embedded tissue.
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Methods
Patients
23 cases of  formalin-fixed, paraffin-embedded
tissue blocks of nasopharyngeal carcinoma diagnosed
in 2005 were retrieved from the archives of
Department of  Pathology, Ibn Rushd University
Medical Center, Casablanca, Morocco. All patients
were diagnosed, treated and followed up at the
Oncology and Radiotherapy Department of  the Ibn
Rushd University Medical Center. Clinical and
pathological aspects such as age, sex and histological
types were abstracted from reports and clinical
records.
Histology classification
The histological classification of nasopharyngeal
carcinoma proposed by the World Health
Organisation (WHO) in 1978, categorized tumours
into three groups based on their degrees of
differentiation 11: type I (WHO-1) is keratinising
squamous-cell carcinomas (SCC), type II (WHO-2)
is non-keratinising squamous carcinomas (NKC) and
type III (WHO-3) is typical undifferentiated
carcinomas (UC). An alternative classification has
divided tumours into two histological types, namely
squamous-cell carcinomas (WHO type I) and
undifferentiated carcinomas of the nasopharyngeal
(WHO types II and III)12,29.
Immunohistochemical staining for LMP1 and
p53 proteins
LMP1 and p53 staining was performed on 23 NPC
specimens. The LSAB detection system (ScyTek kit)
was employed to detect the expression of both
proteins. Briefly, a 4-µm-thick section was cut from
each paraffin archival block and mounted on treated
slides. After heating at 60 °C for 30 min, the tissue
sections were dewaxed in toluene, rehydrated in
ethanol and rinsed in distilled water for 5 min.
Antigen availability for p53 was enhanced by
pretreatment for 30 minutes at 99°C in Tris-EDTA
buffer, pH 9.





for 10 min and nonspecific
binding was blocked with protein blocker for 5 min.
Sections were incubated with primary antibody for
30 min. Primary antibodies used in this study were
anti-LMP1 (1:100 dilution) (clone CS1–4, Dako) and
anti-p53 protein (1:50 dilution) (clone DO-1,
Immunoteck) which reacts with both wild and
mutant types of p53 protein. Immunobinding of
anti-LMP1 and p53 was visualized with biotin-
labeled secondary antibodies and streptavidine-
peroxidase complexes with use of diaminobenzidine
‘DAB’ as a chromogenic substrate (DAB
Chromogenic kit, ScyTek). Sections were
counterstained with Harris hematoxylin, which
enhanced visualization of tissue architecture and
cytological details, and mounted with Eukitt.
A Hodgkin’s disease EBV-induced and squamous
cell carcinoma of  cervix tissue sections known to
be immunoreactive for LMP1 and p53 staining
respectively, was included in every batch as an external
positive control. Negative controls were performed
by substituting the primary antibody with an antibody
diluent in parallel assays of  each tumor. The LMP1
and p53 were localized and quantitated by
microscopic evaluation of cytoplasmic and nuclear
staining respectively.
Analysis of LMP1 and p53 reactivity
LMP-1 expression was considered positive when
more than 10% of neoplastic cells showed a
membrane pattern of staining and p53 expression
was considered positive if nuclear staining was found
in more than 10% of  neoplastic cells.
Statistical analysis
Statistical significance among categorical data was
evaluated using the Fisher’s exact probability test.
Probability values less than 0.05 were considered to
be significant. LMP1 and p53 expressions were
analyzed as qualitative variables, according to various
clinicopathological parameters. The statistical analyses
were performed using Epi-Info 3.5.1 software.
Results
Clinical and histological data
The male: female ratio was 2.28:1, with 16 men and
7 women. The ages were ranged between 10 and
68 years (mean age, 42 ± 16.47 years). Age was not
specified for two patients.
23 primary NPC cases consisted of 7 cases (30.4%)
of differentiated nonkeratinizing carcinoma (NKC,
WHO type 2) and 16 cases (69.6%) of
undifferentiated carcinoma (UC, WHO type 3)
according to World Health Organization
classification. No cases of keratinized squamous cell
carcinoma (SCC, WHO type 1) have been reported.
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Table 1:  p53 protein detection in NPC specimens: correlation with clinical and histopathological
data
Correlative Specimens        Immunohistochemical
expression of p53 protein                P value*
data No. (%) Negative n (%)        Positiven  (%)  
Sex     
Male          16 (69.6)       10 (62.5)                 6 (37.5)                   0.53
Female                     7 (30.4)       5 (71.4)                 2 (28.6)
Age (years)     
< 30          5 (23.8)       5 (100)                 0 (0)                       0.06
> 30       16 (76.2) 8 (50)          8 (50)
Histological type     
SCC       0 (0) 0 (0)           0 (0)
NKC          7 (30.4)       4 (57.1)                 3 (42.9)                    0.46
UC 16 (69.6)            11 (68.8)    5 (31.3)
LMP1 expression
Immunohistochemical analysis for EBV encoded
LMP-1 expression in 23 NPC cases did not reveal
any positive immunostaining. The negative control
showed no immunoreactivity (LMP1 negative). The
positive control showed LMP1 reactivity manifested
by a cytoplasmic staining of Reed Sternberg cells
specific for Hodgkin’s disease. No background was
detected.
p53 expression
An immunohistochemical staining method was used
to identify and measure p53 expression. Among 23
examined specimens, 8 (34.8%) showed positive
staining for the p53 protein and 15 (65.2%) showed
no detectable p53 protein in tumor cells. As
previously reported for NPC, the p53 staining was
restricted to the nuclei of tumor cells, no cytoplasmic
staining was observed (figure 1). The intensity of
immunostaining was heterogeneous among tumor
nuclei: some were strongly labeled, others were less.
The pattern of labeling intensity was also variable
among cases: some cases only showed some intensely
immunostained cells while others showed positive
cells scattered throughout the tumor cell nest.
Table 2: Variation of  the expression of  p53 expression according to NPC endemic areas risk in the
World
 Taiwan Morocco Greece
NPC endemic risk high intermediate      low
p53 expression (%) 95 [38] 34.7  15.9 [33]
B A
Figure 1:  p53 protein staining on: A/ positive control (squamous cell carcinoma of  cervix cancer)
B/ tissue section of  a NPC biopsy. Immunohistochemical staining with light Harris hematoxylin
counterstain. (400 x)
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The correlations between p53 expression and
histological type, age, and sex distribution were tested
and are summarized in table 1. Among the p53-
positive patients, 37.5% were men and 28.6% were
women (P > 0.05). All the patients overexpressing
the p53 protein were older than 30 years old (P=
0.06). By correlating p53 expression with
histopathological type, positive staining was observed
in 3 of 7 (42.9 %) nonkeratinizing carcinomas and
in 5 of 16 (31.3 %) undifferentiated carcinomas (P
> 0.05).
Discussion
The data we reported may not reflect the situation
in the general population, especially as we worked
on a size-reduced series (23 cases), but our results
are in keeping with those previously reported. In
fact, we found that males were more affected by
nasopharyngeal cancer than females (69.5% versus
30.4% respectively) with a sex ratio of 2.28. This
was consistent with other previous data where the
sex ratio ranged between 2 and 3.5 for men30. A
previous Moroccan study also reported a sex ratio
of 2.448. Several epidemiological studies have
revealed a bimodal pattern for North African NPCs.
Whereas in Southeast Asia there is only one single
peak of incidence about the age of 50 years, in
North Africa an additional minor peak of incidence
occurs between the ages of 10-20 years, including
around 15% of all NPC patients10,30,31. Our study
showed a maximum NPC frequency in older patients,
but unlike other studies in North Africa, we couldn’t
highlight the second peak corresponding to juvenile
forms. This was probably due to the fact that the 23
patients diagnosed were mostly adults as confirmed
by the mean age of our series (42 years).
We also noticed a predominance of
undifferentiated carcinomas (UC, WHO type III)
(69.5%) compared with non-keratinising carcinomas
(NKC) (30.4%), whereas keratinising squamous-cell
carcinomas (SCC, WHO type II) were non-existent.
This was quite logical considering that Morocco is a
NPC intermediate risk area and that, in those regions,
the vast majority of NPC belongs to the most
undifferentiated forms, namely WHO types II and
III30.
Through this work, we studied for the first time in
Morocco the expression of LMP1 protein and
overexpression of  p53 protein in NPC patients.
We have not detected the presence of  LMP1
in our sample, unlike other studies that have reported
its expression in 50% to 65% of  EBV-positive NPC
cells29. An immunohistochemical detection of LMP1
performed on 52 Spanish patients showed a
positivity of 78.4%32, what was inconsistent with
another study where a single LMP1 positive  case
belonging to the undifferentiated NPC (WHO type
3) have been detected on a series of 44 cases33. The
non-detection of LMP1 disallowed us from
establishing any association between this protein
expression and other clinicopathological parameters.
However, we can attribute the lack of LMP1
expression in our series to various reasons. First, there
are differences in technical procedures which could
explain the heterogeneity of results: indeed it is
reported that the immunohistochemical technique
may be less sensitive than Western blot (65% of
positivity) or RT-PCR (approximately 100% of
expression) for the detection of LMP134. Some
authors also take into consideration the quality of
the used anti-LMP1 clone; it appears that S12 or
anti-136 clones provide better results in terms of
sensitivity than the CS 1-4 clone10. This also can be
due to a limitation of the immunohistochemical
technique on fixed tissue, since some studies have
reported 20-30% of LMP1 responsiveness on NPC
frozen tissues versus 0% of expression in paraffin-
embedded tissues33. Another possible reasons such
as the adopted detection threshold 10, the methylation
phenomenon of the LMP1 genome that plays an
important role in this gene regulation in NPC
tumors35, the existence of various subsets of LMP1
with different transformation abilities36,37 or the
restriction of the LMP1 expression  to some
unknown stages of NPC development may also
explain this non-detection of LMP1 expression in
our series.
Support for the possible role of p53 in
carcinogenesis comes from a series of  observations
made in NPCs and in other types of  cancer. In
normal cells, the p53 protein had a very short half-
life. By contrast, p53 gene mutations generally lead
to stabilization of the protein (a longer half-life),
which can be detected by immunohistochemistry, a
very simple, fast and reliable standardized method
commonly used in the studies of p53 overexpression.
In our study, p53 was expressed in 34.7%
of cases (8 / 23). This percentage was higher than
that of a Greek study where 15.9% of reactivity
was observed33 but lower than other study
conducted in Taiwan where the positivity of  p53
was estimated at 95% 38. This difference in p53
expression levels cannot be entirely explained by the
antibody clone used since, although we used the DO-
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1 clone while the majority of the studies carried out
used the anti-p53 DO-7 clone, a comparative
research have shown that these two antibody clones
had the same detection sensitivity and specificity39.
However, this work, that have evaluated seven
monoclonal antibodies against p53, also showed that
the 1801 clone used in the Taiwanese study, was less
sensitive and less specific than both DO-1 and DO-
7 antibodies39. On the other hand, the disparity of
p53 expression results between these three studies
may suggest a biological variability of  tumors
according to geographical location and we could
talk about a p53 expression frequency depending
of  the NPC endemic areas (table 2), since in Taiwan
which is a highly NPC endemic area, a significant
overexpression of  p53 was observed compared to
Morocco (NPC intermediate risk) and to Greece
where the NPC is lowly endemic.
A study achieved by Khabir et al.  showed
that there was an accumulation of p53 protein
depending of the age: indeed in North African
population, this protein was highly expressed (81%)
in elderly patients (e” 30 years) compared with
patients under 30 years (38%). This difference in p53
expression between the two age groups may be due
to the fact that patients under 30 years have only one
or two copies of EBV genome per malignant cell
whereas this number is much higher in adults (an
average of 10 copies of EBV genome per malignant
cell). This tends to prove the existence of p53/EBV
interactions and suggests that NPC cells use, for the
two age groups, two distinct pathways to escape to
apoptosis and continue their malignant
transformation. In our study, all patients who
expressed p53 had more than 30 years, however it
wasn’t a significant association (p = 0, 06), probably
due to the lack of power of the statistical test resulting
from the small sample size. Regarding histological
types, we found no significant difference between
the p53 overexpression and the degree of NPC
differentiation (p= 0,46). Other studies also showed
no correlation between p53 expression and
histological type, stage, age and sex distributions of
NPC 38,40.
The majority of the studies on p53 genetic
abnormalities in human cancers focused on exons 5
to 8, the mutation ‘hot-spot’ region which codes for
the DNA binding domain of p53 protein41.
However, in nasopharyngeal carcinoma, nearly all
studies on p53 gene alterations reported a low
percentage (less than 20%) or absence of mutation
in NPC tumor tissues 42,43 although p53 protein was
overexpressed 28. As well, a recent study on 53 NPC
samples found no mutation in exons 5 to 8 of p53
protein, despite 87% of them having high intensity
of p53 expression44. This finding of p53
accumulation in NPC tissues, in the absence of a
mutation in the ‘hot-spot’ region of the gene,
established that high expression of its protein in NPC
cells was not associated with mutation in the p53
DNA-binding domain44.
Indeed, stabilization of the p53 may also be achieved
through the formation of  complexes between
cellular gene product or viral oncoprotein and wild-
type p53 protein45.
It has already been shown that the p53
protein can bind to cellular proteins, such as the
mdm2 oncogene product and heat-shock protein
70 and to several DNA tumor virus proteins,
including SV40 T antigen and E1b protein from
adenovirus type 5, leading to its stabilized
accumulation and inactivation38, 40. Moreover, the
ability of EBV and its genes products in stabilizing
or accumulating p53 protein cannot be ignored, fact
confirmed by the highly significant association
between EBV infection and p53 overexpression in
NPC and the presence of  EBV-encoded proteins
that can bind and inactivate the p53 oncoprotein 45,46,47.
Thus, it is possible that one or multiple EBV genes
products interact with p53 and ultimately cause its
nuclear accumulation. This possibility is supported
by many studies identifying two EBV proteins,
BZLF1 and EBNA5, which are capable of binding
p53 protein 46,47. Of these two proteins, EBNA5
has not been detected in NPCs, whereas a direct
interaction between BZLF1 protein and p53 protein
has been demonstrated. Hence, overexpression of
wild-type p53 protein inhibits the ability of BZLF1
protein to disrupt viral latency; likewise BZLF1
protein inhibits p53-dependent trans-activation 45.
Thus, in the NPC cells, p53 is detected in the wild-
type configuration and would be probably
inactivated by binding to EBV viral proteins resulting
in its nuclear accumulation and probable
compromised function.
Further investigation, using other techniques, of the
molecular and biological changes that occur during
carcinogenesis and progression of NPC can provide
new insight into the pathology of  this disease in
Morocco and could add biological factors that can
be used as new prognostic markers.
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Conclusion
This study confirms that p53 overexpression is
present in a subset of  Moroccan NPC patients. Our
results are consistent with those reported by other
studies concerning the same NPC endemic risk area
and provide original data concerning Morocco.
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